| Project/Area Number |
26861390
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Kyushu University (2016)
National Cancer Center Japan (2014-2015) |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
HAYASHI Ryuichi
FUJII Satoshi
MUKAIGAWA Takashi
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 頭頸部癌 / 唾液腺癌 / 遠隔転移 / 病理 / 個別化治療 / 分子標的治療 / ezrin / HER2 / 病理組織学 / 病理学 |
|---|
| Outline of Final Research Achievements |
Salivary gland carcinomas (SGCs) exhibit heterogeneous biological behaviors. The aim of the present study was to investigate the relationship between ezrin expression and the expression of HER2, p53, and Ki-67 as well as clinicopathological factors in 221 SGC patients. High ezrin expression detected in samples from 63 (28.5%) patients significantly correlated with high-grade histopathology, high expression of Ki-67, HER2, p53, and distant metastasis. Multivariate analysis demonstrated that high ezrin expression was an independent prognostic factor for shorter overall survival. Further, concomitant expression of ezrin and HER2 correlated significantly with shorter overall survival as well as a high incidence of distant metastasis. These findings indicate that ezrin and HER2 expression in patients with SGCs represents a high-grade histopathological subtype that requires adjuvant therapy, including molecularly targeted therapies, to decrease the risk of subsequent metastasis.
|
